A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy

Hiromitsu Hoshino, Yutaka Takeda, Hiroaki Nagano, Shoji Nakamori, Shogo Kobayashi, Hidetoshi Eguchi, Shigeru Marubashi, Masahiro Tanemura, Toru Kitagawa, Koji Umeshita, Morito Monden, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer. On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising. We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1. and gemcitabine combination chemotherapy. A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease. Pancreatoduodenectomy with regional lymph node dissection was performed after preoperative chemoradiotherapy. Pathological examination revealed a poorly differentiated adenocarcinoma. A solitary hepatic metastasis was detected by CT imaging one year after the surgery. The patient received 35 courses of S-1. and gemcitabine combination therapy. The metastatic tumor was disappeared, and serum CEA decreased to a normal level. S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe. This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.

Original languageEnglish
Pages (from-to)2419-2421
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number12
Publication statusPublished - Nov 2009

Fingerprint

gemcitabine
Pancreaticoduodenectomy
Combination Drug Therapy
Pancreatic Neoplasms
Neoplasm Metastasis
Survival
Liver
Chemoradiotherapy
Therapeutics
Head and Neck Neoplasms
Lymph Node Excision
Adenocarcinoma
S 1 (combination)

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy. / Hoshino, Hiromitsu; Takeda, Yutaka; Nagano, Hiroaki; Nakamori, Shoji; Kobayashi, Shogo; Eguchi, Hidetoshi; Marubashi, Shigeru; Tanemura, Masahiro; Kitagawa, Toru; Umeshita, Koji; Monden, Morito; Doki, Yuichiro; Mori, Masaki.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 36, No. 12, 11.2009, p. 2419-2421.

Research output: Contribution to journalArticle

Hoshino, H, Takeda, Y, Nagano, H, Nakamori, S, Kobayashi, S, Eguchi, H, Marubashi, S, Tanemura, M, Kitagawa, T, Umeshita, K, Monden, M, Doki, Y & Mori, M 2009, 'A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy', Japanese Journal of Cancer and Chemotherapy, vol. 36, no. 12, pp. 2419-2421.
Hoshino, Hiromitsu ; Takeda, Yutaka ; Nagano, Hiroaki ; Nakamori, Shoji ; Kobayashi, Shogo ; Eguchi, Hidetoshi ; Marubashi, Shigeru ; Tanemura, Masahiro ; Kitagawa, Toru ; Umeshita, Koji ; Monden, Morito ; Doki, Yuichiro ; Mori, Masaki. / A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy. In: Japanese Journal of Cancer and Chemotherapy. 2009 ; Vol. 36, No. 12. pp. 2419-2421.
@article{c2821a20644549e4a3cf9b70a1d082d7,
title = "A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy",
abstract = "Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer. On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising. We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1. and gemcitabine combination chemotherapy. A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease. Pancreatoduodenectomy with regional lymph node dissection was performed after preoperative chemoradiotherapy. Pathological examination revealed a poorly differentiated adenocarcinoma. A solitary hepatic metastasis was detected by CT imaging one year after the surgery. The patient received 35 courses of S-1. and gemcitabine combination therapy. The metastatic tumor was disappeared, and serum CEA decreased to a normal level. S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe. This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.",
author = "Hiromitsu Hoshino and Yutaka Takeda and Hiroaki Nagano and Shoji Nakamori and Shogo Kobayashi and Hidetoshi Eguchi and Shigeru Marubashi and Masahiro Tanemura and Toru Kitagawa and Koji Umeshita and Morito Monden and Yuichiro Doki and Masaki Mori",
year = "2009",
month = "11",
language = "English",
volume = "36",
pages = "2419--2421",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by S-1 and gemcitabine combination chemotherapy

AU - Hoshino, Hiromitsu

AU - Takeda, Yutaka

AU - Nagano, Hiroaki

AU - Nakamori, Shoji

AU - Kobayashi, Shogo

AU - Eguchi, Hidetoshi

AU - Marubashi, Shigeru

AU - Tanemura, Masahiro

AU - Kitagawa, Toru

AU - Umeshita, Koji

AU - Monden, Morito

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2009/11

Y1 - 2009/11

N2 - Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer. On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising. We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1. and gemcitabine combination chemotherapy. A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease. Pancreatoduodenectomy with regional lymph node dissection was performed after preoperative chemoradiotherapy. Pathological examination revealed a poorly differentiated adenocarcinoma. A solitary hepatic metastasis was detected by CT imaging one year after the surgery. The patient received 35 courses of S-1. and gemcitabine combination therapy. The metastatic tumor was disappeared, and serum CEA decreased to a normal level. S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe. This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.

AB - Gemcitabine monotherapy is accepted as a standard first-line treatment for locally advanced unresectable or metastatic pancreatic cancer. On another front, S-1 and gemcitabine combination chemotherapy is challenging but promising. We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1. and gemcitabine combination chemotherapy. A 59-year-old woman was diagnosed as locoregionally advanced pancreas head cancer without metastatic disease. Pancreatoduodenectomy with regional lymph node dissection was performed after preoperative chemoradiotherapy. Pathological examination revealed a poorly differentiated adenocarcinoma. A solitary hepatic metastasis was detected by CT imaging one year after the surgery. The patient received 35 courses of S-1. and gemcitabine combination therapy. The metastatic tumor was disappeared, and serum CEA decreased to a normal level. S-1 and gemcitabine combination therapy is not only effective but also well tolerated and safe. This combination therapy should be considered one of selective choices for advanced or metastatic pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84864598698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864598698&partnerID=8YFLogxK

M3 - Article

C2 - 20037442

AN - SCOPUS:84864598698

VL - 36

SP - 2419

EP - 2421

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -